[6-K] BioNTech SE Current Report (Foreign Issuer)

Rhea-AI Filing Summary

BioNTech SE submitted a Form 6-K reporting that it issued a press release on November 26, 2025 about its exchange offer for all outstanding shares of CureVac N.V.. The press release announces the results of CureVac’s extraordinary general meeting and the calculation of the exchange ratio for the offer.

The filing states that this Form 6-K is incorporated by reference into BioNTech’s Form F-4 registration statement. The attached press release, filed as Exhibit 99.1, highlights progress on the exchange offer and notes a December 3, 2025 at 9:00 a.m. Eastern Time expiration for the offer.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF NOVEMBER 2025

COMMISSION FILE NUMBER 001-39081

BioNTech SE

(Translation of registrant’s name into English)

An der Goldgrube 12

D-55131 Mainz

Germany

+49 6131-9084-0

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

On November 26, 2025, BioNTech SE (the “Company”) issued a press release announcing the results of the CureVac N.V. (“CureVac”) extraordinary general meeting and the calculation of the exchange ratio in connection with its exchange offer for all outstanding shares of CureVac. A copy of the press release is attached hereto as Exhibit 99.1.

This report on Form 6-K shall be deemed to be filed and incorporated by reference in the Company’s registration statement on Form F-4 (File No. 333-289468) and to be part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioNTech SE
By:		/s/ Prof. Dr. Ugur Sahin				By:		/s/ Dr. Sierk Poetting
		Name: Prof. Dr. Ugur Sahin						Name: Dr. Sierk Poetting
		Title: Chief Executive Officer						Title: Chief Operating Officer

Date: November 26, 2025

EXHIBIT INDEX

Exhibit		Description of Exhibit
99.1		BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025 at 9:00 a.m. Eastern Time Expiration

FAQ

What did BioNTech (BNTX) announce in this Form 6-K?

BioNTech SE reported that it issued a press release providing the results of CureVac N.V.’s extraordinary general meeting and the calculation of the exchange ratio for BioNTech’s exchange offer for all outstanding CureVac shares.

How does the CureVac exchange offer relate to BioNTech’s Form F-4?

The Form 6-K states that it is deemed filed and incorporated by reference into BioNTech’s Form F-4 registration statement (File No. 333-289468), making the exchange offer update part of that registration.

When does BioNTech’s exchange offer for CureVac shares expire?

According to the description of Exhibit 99.1, the exchange offer for CureVac shares highlights a December 3, 2025 at 9:00 a.m. Eastern Time expiration.

What is contained in Exhibit 99.1 to BioNTech’s Form 6-K?

Exhibit 99.1 is a press release titled “BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025 at 9:00 a.m. Eastern Time Expiration.”

Who signed the BioNTech Form 6-K related to the CureVac exchange offer?

The Form 6-K was signed on behalf of BioNTech SE by Prof. Dr. Ugur Sahin, Chief Executive Officer, and Dr. Sierk Poetting, Chief Operating Officer.

What corporate action at CureVac is referenced by BioNTech?

BioNTech references CureVac N.V.’s extraordinary general meeting, whose results are discussed in the attached press release in connection with the exchange offer.